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Background: Asthma guidelines suggest that therapy can be reduced once asthma is controlled. Despite these
recommendations, asthmatic patients are seldom stepped down in clinical practice, and questions remain about
when and how to reduce asthma therapy. The purpose of the present study was to evaluate lung function and
asthma control in patients who were stepped down from the highest recommended dose of inhaled
corticosteroid/long acting β2 agonist combination therapy.
Methods: This was a prospective, randomised, controlled, two-arm parallel group study. Asthmatic patients who
were fully controlled with a high daily dose (1000/100 μg) of fluticasone/salmeterol were randomly assigned to
6 months of open-label treatment with either 500/100 μg fluticasone/salmeterol Diskus daily or 400/24 μg extrafine
beclomethasone/formoterol pMDI daily. The primary outcome was the change in morning peak expiratory flow
(PEF) values between baseline and the end of treatment. The secondary outcomes included asthma control and
exacerbation frequency.
Results: Four hundred twenty-two patients were included in the analysis. The PEF values remained above 95% of
the predicted values throughout the study. The end-study morning PEF rates showed equivalence between the
groups (difference between means, 2.49 L/min; 95% CI, -13.43 to 18.42). No changes from baseline were detected in
PEF and forced expiratory volume in 1 second measured at the clinics, in the symptom scores or in the use of
rescue medication. Asthma control was maintained in 95.2% of the patients at 6 months. No significant differences
between the groups were detected in any other parameter, including exacerbation frequency and adverse events.
Conclusions: Stepping down patients whose asthma is controlled with the highest recommended dose of
fluticasone/salmeterol to either 500/100 μg fluticasone/salmeterol daily or 400/24 μg extra-fine beclomethasone/
formoterol daily provides comparable maintenance of lung function and asthma control.
Trial registration: clinicaltrials.gov NCT00497237
Keywords: Beclomethasone, Extrafine, Fluticasone, Formoterol, Salmeterol* Correspondence: ppa@unife.it
1Research Center on Asthma and COPD, University of Ferrara, Via Savonarola
9, 44100, Ferrara, Italy
Full list of author information is available at the end of the article
© 2012 Papi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Papi et al. Respiratory Research 2012, 13:54 Page 2 of 10
http://respiratory-research.com/content/13/1/54Background
International guidelines recommend a stepwise approach
for managing asthma in adults and children over 5 years
of age [1]. The Global Initiative for Asthma (GINA)
guidelines [1] indicate that “asthma control” is the ob-
jective of treatment, i.e., achieving and maintaining the
control of symptoms and normal activity levels, main-
taining pulmonary function as close to normal as pos-
sible, preventing asthma exacerbations and asthma
mortality and avoiding adverse effects from asthma med-
ications. Maintenance treatment should be stepped up
or stepped down to the minimum amount of medication
necessary to maintain asthma control and minimise the
potential for long-term side effects [1].
Inhaled corticosteroids (ICS) represent the cornerstone
of maintenance treatment. If asthma control is inadequate
with low-dose ICS, the addition of a long-acting β2-
agonist (LABA) provides enhanced clinical benefits com-
pared to increasing the ICS dosage [2-4]. ICS and LABAs
have complementary clinical and pharmacological activ-
ities when administered together [5].
Although asthma guidelines advocate reducing treat-
ment once asthma is well controlled [1,6], clinicians ap-
pear to be reluctant to reduce treatment. Both treatment
prescription surveys and clinical trials indicate that a
large proportion of asthmatic patients are over-treated
and seldom stepped-down in clinical practice [7,8].
Relatively few studies have evaluated the best strategy
for dose reduction [7,9-11]. Some studies have docu-
mented a better maintenance of asthma control when
the patients who are treated with ICS/LABA combin-
ation treatments were stepped down to a lower dose of
the ICS/LABA combination, as opposed to suspending
the LABA while maintaining the ICS at the same dose
[7,10,11]. This step-down strategy has the advantage of
maintaining asthma control and lowering the dose of
ICS [7]. Conversely, 2 studies have shown that stepping-
down from a low dose of ICS or the ICS/LABA combin-
ation to montelukast leads to a deterioration of asthma
control [12,13]. To date, no studies have assessed a treat-
ment step-down to different drug combinations that are
delivered by different inhaler devices (dry powder and
pressurised metered dose inhalers).
In terms of symptoms and pulmonary function im-
provement, extra-fine beclomethasone/formoterol com-
bination therapy has demonstrated comparable efficacy
to other ICS/LABA combinations containing higher
nominal doses of ICS [14,15]; however, these treatments
have not been compared in a step-down treatment
strategy.
The aim of this study was to compare the efficacy of
an extra-fine beclomethasone/formoterol combination
to that of a medium dose fluticasone/salmeterol combin-
ation in maintaining lung function and asthma controlfollowing a step-down in subjects whose asthma was
controlled with a high dose ICS/LABA combination.
Methods
Patients
This study was carried out in 67 Respiratory Clinics in
Europe. Outpatients who were 18–65 years old and
had been diagnosed with asthma for at least 6 months
were enrolled in the study if they had been treated
with 1000 mcg fluticasone propionate + 100 mcg salme-
terol daily for ≥ 4 weeks before the screening visit and
had features of controlled asthma, which was defined
in the following manner: forced expiratory volume in
one second (FEV1) or peak expiratory flow (PEF) values
> 80% of the predicted normal values, no nocturnal
symptoms or awakenings, no exacerbations, no limita-
tions of activities, and daytime symptoms and use of
rescue medication ≤ 2 days per week in the 4 weeks
previous to the screening visit.
Those patients satisfying any of the following criteria
were excluded: a diagnosis of chronic obstructive pul-
monary disease (COPD), as defined by the GOLD guide-
lines [16]; current or ex-smokers (≥ 10 packs/year); a
history of near fatal asthma; a symptomatic infection of
the airways in the previous 8 weeks; ≥ 3 courses of oral
corticosteroids or hospitalisation due to asthma in the
previous 6 months, treatment with anticholinergics and
antihistamines during the previous 2 weeks, or treat-
ment with topical or intranasal corticosteroids and leu-
kotriene antagonists during the previous 4 weeks.
The study was performed in accordance with the
Good Clinical Practice guidelines recommended by the
International Conference on Harmonization of Tech-
nical Requirements. The protocol was approved by the
institutional review board of each centre, and written
informed consent was obtained from each participant
prior to the initiation of the study.
Study design
This was a prospective, randomised, controlled, multi-
national, multi-centre, open, two-arm parallel group
study. Asthma control was reassessed after an 8-week
run-in period during which the patients continued
treatment with 1000 μg fluticasone propionate/100 μg
salmeterol daily. Those patients with controlled asthma
in each of the last 4 weeks of the run-in were rando-
mised to a 24-week treatment period with either
250/50 μg fluticasone/salmeterol (FP/S) Diskus DPI
(SeretideW, GlaxoSmithKline, Middlesex, UK) or 100/6 μg
beclomethasone/formoterol (BDP/F) pMDI (FOSTERTM,
Chiesi Farmaceutici, Parma, Italy). The patients in the
FP/S group were treated with one inhalation twice daily
(daily dose 500 μg fluticasone/100 μg salmeterol). The
patients in the BDP/F treatment group were treated
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beclomethasone/24 μg formoterol). The patients were
randomised according to the pre-determined balanced-
block randomisation list that was computer-generated
for each centre. Concealed random allocation was done
by using a fully automated functionality built into the
electronic Case Report Form (e-CRF). The study group
was electronically assigned to any new patient by the
system and was associated to a patient number with no
possibility for the study staff of changing the random al-
location. Clinic visits were performed monthly for a
total of 9 visits throughout the entire study. Inhaled res-
cue salbutamol use was permitted at any time, and oral
corticosteroids were permitted only in the case of
asthma exacerbation. No other anti-asthma medication
was permitted at any time.
Protocol outcome measures
The primary outcome was the change in morning peak
expiratory flow (PEF) rate from baseline to the end of
the treatment period (mean of weeks 23–24).
Secondary outcomes included asthma control, lung
function, exacerbations, symptoms and rescue medica-
tion use.
Asthma control was assessed using the GINA compos-
ite measurements, with each week being classified as
"uncontrolled", "partly controlled" or "controlled" based
on the following parameters: daytime symptoms, limita-
tion of activities, nocturnal symptoms/awakenings, use
of rescue medication, lung function and exacerbations
[1]. The pulmonary function tests (PFTs) were per-
formed at each visit to the clinic in accordance with
standard procedure, prior to study drug intake and at
least 12 hours after the previous evening dose and 6
hours after the previous salbutamol dose. The morning
dose of the study drugs was taken after the PFTs were
performed at the clinic sites, under the investigator’s
supervision, to assess proper inhaler technique.
The patients used a portable flow meter (Piko-1, Fer-
raris Louisville, CO, USA) in compliance with ATS
standard 2004 to measure their morning and evening
PEF values prior to the study drug intake and 6 hours
from the previous salbutamol dose. The PEF values were
downloaded at each visit to the study centre and directly
entered in the e-CRF using dedicated software. The
patients recorded asthma symptom scores (0–5) and res-
cue salbutamol intake twice daily on a diary card.
The investigator evaluated the occurrence of asthma
exacerbations at all post-baseline visits upon reviewing
the diary card with the patient, with extensive inquiry if
needed. A mild exacerbation was defined as ≥ 2 consecu-
tive days with morning PEF readings more than 20%
below the baseline value, the use of> 3 additional inha-
lations of rescue salbutamol compared to baseline orawakening at night due to asthma [14,15]. A severe ex-
acerbation was defined as morning PEF readings more
than 30% below baseline values on ≥ 2 consecutive days
or the deterioration of asthma requiring administration
of oral corticosteroids [14,15]. Adverse events (AEs)
were recorded throughout the study period.Statistics
The study was designed to evaluate the equivalence of
beclomethasone/formoterol treatment and fluticasone/
salmeterol treatment after step-down. The primary effi-
cacy variable was the change in morning PEF values
from the baseline values to the end of the treatment
period. This variable was analysed by means of the
ANCOVA model, with the treatment and the centre
used as fixed factors and the baseline PEF values used as
a linear covariate. Equivalence was proved if the adjusted
two-sided 95% confidence interval for the mean change
difference between the two treatments was entirely
within the interval of −20 to +20 L/min. Estimating an
alpha error set to 0.05 (two-sided), a standard deviation
of 60 L/min and an expected difference between means
equal to zero, a total of 191 patients were required in
each group to have 90% power to satisfy the above
hypothesis.
The baseline values for the variables recorded on the
diary cards and the daily PEF measurements were the
mean values of the last 2 weeks of the run-in period.
The values that were measured in the randomisation
visit (end of the run-in) were considered baseline values
for the variables measured at the clinics. The last 4 weeks
of the run-in period were considered to be the asthma
control baseline values.
Efficacy analysis was made on intention-to-treat (ITT)
population including all subjects who had been rando-
mised to treatment and had at least one recording after
randomisation. The imputation of missing primary effi-
cacy variable data was performed using the last observa-
tion carried forward (LOCF) method for post-baseline
data. Additionally, to ensure that the handling of missing
data did not lead to misinterpretation, the analysis was
repeated using the main ANCOVA model adopting the
expectation maximisation (EM) algorithm.
P-values for the adjusted means were based on the
ANCOVA model, whereas differences between treat-
ment groups were evaluated using a chi-square test or a
two-tailed Fisher’s exact test. The analysis of the time to
first asthma exacerbation was performed using the
Kaplan-Meier method. Safety was analysed in all of the
randomised patients who received at least 1 dose of
study medication. All of the statistical analyses were per-
formed using SAS system version 9.1.3 (SAS Institute
Inc., Cary, NC).
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In total, 562 patients were screened between April 2007
and July 2009 (Figure 1). Out of the 442 randomised
patients, 440 showed evidence of study drug intake and
were analysed for safety, 422 had baseline data and at
least one assessment of the secondary efficacy variables
after randomisation (ITT) and 378 had baseline data and
at least one assessment of the primary efficacy variable
after randomisation. The baseline data (Table 1) from
the two groups were well matched (p> 0.05 for all com-
parisons). The patient compliance, as evaluated from the
diary cards, was >95% in both groups during the run-in
and >90% during the step-down period.
Lung function
The morning PEF values were equivalent in the two
treatment groups [397.15 (6.47) L/min and 394.65 (6.49)
L/min in the BDP/F and FP/S groups, adjusted mean
(SE), respectively], exhibiting a difference of 2.49 L/min
(95% CI, -13.43 to 18.42). Equivalence was also con-
firmed with imputation of the missing primary efficacy
variable data using the expectation maximisation algo-
rithm, which showed a difference of 1.63 L/min between
the BDP/F and FP/S groups (95% CI, -14.49 to 17.76).
Similarly, the per protocol analysis (including all subjects
of the ITT population without major protocol devia-
tions, n = 360) showed a 4.25 L/min difference between
the treatment means (95% CI, -11.87 to 20.38). NoFigure 1 A flow-chart representing patient flow. BDP/F, beclomethason
The reasons for screening failure and withdrawal were derived from the studifference between groups was detected in any lung func-
tion parameter (Table 2). The PEF values remained above
95% of the predicted values throughout the study period
(Figure 2). The morning PEF absolute values that were
measured by patients (Figure 3) at the end of the study
had decreased slightly from the baseline values (from
414.4 to 397.1 L/min and from 429.7 to 394.6 L/min for
BDP/F and FP/S, respectively; p< 0.05 vs. baseline for
week 14 onwards in both groups). Conversely, no signifi-
cant changes from baseline were detected in the PEF and
FEV1 or the PEF and FEV1% of predicted values that
were measured in the standardised conditions of the
clinic visits (Table 3).Asthma control
Asthma control was maintained in almost all of the
patients throughout the 6-month step-down period, with
the percentage of controlled plus partly controlled
patients always remaining above 93% in both groups
(Figure 4). At the end of the study, the percentage of
patients with controlled and partly controlled asthma
was 96.0% in the BDP/F group and 94.4% in the FP/S
group (Table 2, Figure 4).ICS doses
A significant reduction in the mean ICS dose per
week, when compared with run-in period, was founde dipropionate/formoterol; FP/S, fluticasone propionate/salmeterol.
dy termination form.
Table 1 Baseline characteristics of the patients examined, grouped based on randomised treatment
BDP/F400/24 μg/day (N = 206) FP/S500/100 μg/day (N= 216)
Age (years) 44 (13) 44 (13)
Gender Male 69 (33.5%) 77 (35.6%)
Female 137 (66.5%) 139 (64.4%)
BMI (kg/m2) 27.1 (5.1) 27.0 (5.2)
Device used before screening pMDI 12.6% 12.6%
DPI 87.4% 87.4%
Years from asthma diagnosis 11 (10) 13 (11)
FEV1, L 2.9 (0.9) 3.0 (0.8)
FEV1% predicted 86.9 (15.1) 88.3 (14.1)
PEF, L/min 435.7 (8.3) 452.9 (8.1)
PEF % predicted 97.8 (21.4) 100.5 (20.3)
Number of days/week with symptomsa 0.5 (1.2) 0.3 (0.6)
Number of nights/week with symptomsa 0.3 (1.1) 0.1 (0.6)
Rescue medication use, puffs/weeka 1.2 (0.4) 1.2 (0.4)
Rescue-free days/weekb 6.6 (1.4) 6.6 (1.2)
PEF >80%, days/weekb 5.6 (1.9) 5.5 (1.6)
Controlled asthmab, n (%) 203 (98.5) 212 (98.1)
Partly controlled asthmab, % 2 (1.0) 3 (1.4)
Uncontrolled asthmab, % 1 (0.5) 1 (0.5)
The values are means (SD). a the mean of the last 4 weeks of run-in period, b in each of the last 4 weeks of the run-in period. The lung function values were
measured during the randomisation visit at the end of the run-in. BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone propionate/salmeterol; BMI,
body mass index; FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow.
Papi et al. Respiratory Research 2012, 13:54 Page 5 of 10
http://respiratory-research.com/content/13/1/54in both the FP/S group (6485.6 μg/week vs. 3182.3 μg/
week during the run-in and treatment periods, respect-
ively; p< 0.001) and the BDP/F group (6411.5 μg/week
vs. 2452.0 μg/week during the run-in and treatment
periods, respectively; p< 0.001). The cumulative mean
ICS dose during the 6-month study period was signifi-
cantly lower in the BDP/F group than the FP/S group
(57.66 mg vs. 75.38 mg, respectively; p< 0.001).Table 2 Comparisons between groups at the end of the study
BDP/F400/24 μg/day (N= 206)
FEV1, L 2.92 (0.04)
FEV1% predicted 85.90 (0.98)
PEF, L/min 442.47 (4.57)
PEF % predicted 96.87 (1.46)
Daytime symptoms scorea 1.37 (0.07)
Night-time symptom scorea 1.33 (0.11)
symptom-free days, % 93.66 (1.13)
Controlled asthmab, n (%) 163 (90.0)
Partly controlled asthmab, % 11 (6.0)
Uncontrolled asthmab, % 7 (4.0)
The values are adjusted means (SE). The lung function values were measured durin
cards, b in the last 4 weeks of the treatment period. BDP/F, beclomethasone diprop
expiratory volume in 1 second; PEF, peak expiratory flow.Symptoms and rescue medication use
The diurnal and nocturnal symptom scores were not dif-
ferent between the two groups at the end of the study,
with neither group exhibiting a change from baseline
(Tables 2, 3). The percent of symptom-free days (24 h)
throughout the study was similar between groups
(Table 2). The proportion of patients with no asthma
symptoms throughout the 6-month step-down phaseFP/S500/100 μg/day (N= 216) Between group p value
2.92 (0.03) 0.938
85.70 (0.98) 0.878
440.21 (4.55) 0.699
98.43 (1.32) 0.428
1.32 (0.06) 0.609
1.46 (0.10) 0.368
92.47 (1.11) 0.451
167 (85.2) 0.362
18 (9.2)
11 (5.6)
g the last visit. a the mean of the last 4 weeks of treatment derived from diary
ionate/formoterol; FP/S, fluticasone propionate/salmeterol; FEV1, forced
Figure 2 The morning PEF % predicted values during the run-in and treatment periods (raw means). BDP/F, beclomethasone
dipropionate/formoterol; FP/S, fluticasone propionate/salmeterol.
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63.7% for night-time symptoms in the BDP/F and FP/S
groups, respectively. No significant differences were
detected between the groups (p = 0.69 for daytime and
p = 0.61 for night-time symptoms).
The use of rescue medication remained low through-
out the study, and no differences were observed
between the groups (Figure 5). On average, rescue
medication was used less than one day per week in
both groups during the treatment phase. Overall,
47.8% of the patients in the BDP/F group and 44.7%
of the patients in the FP/S group did not use rescue
medication during the daytime of the 6-month study,
and 71.7% of the patients in the BDP/F group andFigure 3 The morning PEF absolute values during the run-in (raw me
beclomethasone dipropionate/formoterol; FP/S, fluticasone propionate/salm70.2% of the patients in the FP/S group did not use
medication during the night-time. No significant differ-
ences were observed between the groups (p = 0.56 for
daytime and p = 0.75 for night-time).
Asthma exacerbations and adverse events
Sixty-eight of the 440 patients that were evaluated for
safety experienced asthma exacerbations during the 6-
month treatment period. Thirty-one of these patients
were in the FP/S group (14.6% of patients), and 37 were
in the BDP/F group (18% of patients). Severe exacerba-
tions occurred in 2.4% and 1.9% of patients in the FP/S
and BDP/F groups, respectively. No statistically signifi-
cant differences in the frequency of patients with anyans) and treatment periods (adjusted means). BDP/F,
eterol.
Table 3 Changes in the lung function parameters measured at clinic visits in comparison to baseline values
BDP/F400/24 μg/day (N= 206) p value FP/S500/100 μg/day (N = 216) p value
FEV1, L −0.06 (0.03) 0.089 −0.06 (0.03) 0.109
FEV1% predicted −1.72 (0.98) 0.080 −1.91 (0.98) 0.051
PEF, L/min −2.02 (4.57) 0.658 −4.28 (4.55) 0.347
PEF % predicted −0.90 (0.96) 0.349 −1.25 (0.95) 0.190
Daytime symptoms score −0.06 (0.07) 0.327 −0.03 (0.06) 0.661
Night-time symptom score 0.20 (0.11) 0.067 0.07 (0.10) 0.503
The values are the adjusted mean (SE) changes from baseline to the end of the study. BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone
propionate/salmeterol; FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow.
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severe exacerbations (p = 1.00) were detected between
the treatment groups.
The mean (SE) time to first asthma exacerbation was
154.7 (2.3) days in the FP/S group and 143.4 (2.5) days
in the BDP/F group. No significant difference was
observed between the groups (p = 0.36).
Adverse events (AE) were reported in 14.4% of the
patients in the FP/S group and 15.5% of the patients in
the BDP/F group; no differences were observed between
the groups (p = 0.78). There was no difference in the
proportion of patients experiencing AE that led to treat-
ment interruption between the groups. Treatment inter-
ruption occurred in 1 patient (0.4%) in the FP/S group
and 6 patients (2.8%) in the BDP/F group (p = 0.060).
Serious AE occurred in 1.4% and 0.5% of patients in the
FP/S and BDP/F groups, respectively. There were no dif-
ferences in the proportion of patients with serious AE
between the groups (p = 0.62).Figure 4 Asthma control during the run-in period and the treatment
formoterol; FP/S, fluticasone propionate/salmeterol.Discussion
In this study, we found that those patients who have
asthma that is controlled with high dose FP/S can be
stepped down to medium dose ICS/LABA combinations
and still maintain asthma control. No difference in the
morning PEF, asthma control, exacerbation rates and
lung function measured at clinics was found between
the FP/S combination and the extrafine BDP/F pMDI.
Although in clinical practice PEF is seldom used as a
clinical outcome, it is easily determined and is a well-
established outcome measure for monitoring asthma [1]
that is consistent with previous studies, including those
evaluating step-down approaches [10,11,13-15]. In our
study, the PEF values were maintained at levels that
were greater than 95% of the predicted values during the
whole study period, which is above the 80% of predicted
value required in the composite assessment of control
[1]. A significant decrease in the morning PEF values of
the BDP/F group (17.3 L/min) and the FP/S groupperiod (raw means). BDP/F, beclomethasone dipropionate/
Figure 5 Mean number of days/week that rescue medication was used during the run-in and treatment periods (raw means). BDP/F,
beclomethasone dipropionate/formoterol; FP/S, fluticasone propionate/salmeterol.
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with the latter being above the value that is considered
clinically relevant [17]. This decrease in PEF values was
not detected in the PFTs measured at the clinics. Such a
discrepancy is consistent with the findings of the FACET
study [18]. Finally, these changes were detected in both
groups and are unlikely to be due to a lower compliance,
as treatment compliance was greater than 90% during
the step-down phase.
The current international asthma guidelines [1] rec-
ommend that treatment should be reviewed and a re-
duction in the dose of controller medication should be
attempted once asthma control has been achieved and
maintained for 3 to 6 months, with the patients being
carefully monitored to ensure that control is not lost.
This advice is largely based on clinical experience; few
studies have examined treatment step-down options and
the most favourable conditions for dose reduction. The
questions that need to be addressed include whether a
step-down of controller medication can be achieved
without a loss of lung function and asthma control. In
this study, we found that a treatment step-down that
halved the ICS dose maintained asthma control and lung
function in patients whose asthma was previously con-
trolled with a high dose ICS/LABA combination. We
designed the study according to the preferred option
recommended by international guidelines for the step-
down procedure for patients under high dose ICS/LABA
consisting in reducing the ICS dose while maintaining
the LABA [1].
Only a small number of studies have evaluated asthma
control after treatment step-down [7,9-11,19,20], and
this is the first study assessing asthma control based on
the GINA guidelines [1]. We intentionally selected
patients whose asthma was controlled under the highest
recommended dose of the FP/S combination, which isthe most prescribed therapy for obstructive lung diseases
in Europe [21]. Thus, an added value of the study is that
we recruited patients whose asthma was already treated
and controlled with high dose ICS/LABA therapy in real
life, thus identifying candidates for step-down therapy.
In other words, we used a RCT to test if the high ICS
doses utilised to maintain asthma control in real life
conditions can be safely stepped down. Moreover, we
had the advantage of examining patients over a 6-month
period, a longer time frame than most of the previous
studies [7,9,11,13,19,20]. Our results suggest that clinical
decisions should also consider changes occurring after a
prolonged period of observation (6 months).
This study is also the first to demonstrate that patients
with controlled asthma can maintain control if switched
from DPI to pMDI devices while stepping down treat-
ment. The smaller particle size of the beclomethasone/for-
moterol combination, compared to fluticasone/salmeterol
combination [22], which is formulated with larger parti-
cles, enables the ICS and LABA to reach and treat both
the large and small airways, thus ensuring the treatment
of inflammation and bronchoconstriction in the entire
bronchial tree.
As a consequence of stepping down asthma treatment,
the mean ICS dose was reduced by approximately 50%
in the FP/S-receiving patients and 60% in the BDP/F-re-
ceiving patients. This reduction is of particular interest
because long term treatment with high doses of ICS is
associated with significant systemic side effects [1]. A re-
cent study demonstrated that a reduction in the ICS
dose could be achieved in a community setting without
resulting in a worsening of airway inflammation or lung
function and improved the patients’ quality of life [23].
A limitation of the present study is the open design
which does not eliminate the possibility of patient and
physician bias, even if the primary outcome was an
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independent of the investigator. Because of the modality
of data collection (downloaded at each centre and entered
directly in the e-CRF), the blinding of the primary out-
come was not feasible. In addition, an intrinsic limitation
of our study design is that we could not confirm that
patients were on the minimum dose that maintained
asthma control before study start. Thus the overtreatment
quite commonly reported in real life conditions (8) cannot
be excluded. However, patients were selected from pul-
monary centres where they were regularly assessed and
treated according to the current guidelines, suggesting
that the dose of the original ICS/LABA prescription was
appropriate. Finally, the design of our study did not allow
us to evaluate whether further step-downs could have
been performed in order to truly demonstrate the mini-
mum effective dose and thus to decide whether the ICS/
LABA daily dosage was appropriate.Conclusions
The present study demonstrated that 400/24 μg extra-
fine BDP/F daily is equivalent to 500/100 μg FP/S daily
in maintaining lung function and is comparable in main-
taining asthma control in patients who were previously
controlled with the highest recommended dose of FP/S
(1000/100 μg daily). This is one of the few studies show-
ing that asthmatic patients currently treated with com-
bination therapy comprising high dose ICS can be
equally controlled with lower exposure to ICS. More-
over, this is the first study to demonstrate that the ma-
jority of patients who are controlled with high dose ICS/
LABA DPI can be stepped down to medium dose DPI
or extra-fine pMDI combinations and still maintain
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